View in EDS PDF Full Text

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.

Saved in:
Bibliographic Details
Title: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
Authors: Alonso, Pedro L., Sacarlal, Jahit, Aponte, John J., Leach, Amanda, Macete, Eusebio, Aide, Pedro, Sigauque, Betuel, Milman, Jessica, Mandomando, Inacio, Bassat, Quique, Guinovart, Caterina, Espasa, Mateu, Corachan, Sabine, Lievens, Marc, Navia, Margarita M., Dubois, Marie-Claude, Menendez, Clara, Dubovsky, Filip, Cohen, Joe, Thompson, Ricardo
Source: Lancet. 12/10/2005, Vol. 366 Issue 9502, p2012-2018. 7p. 1 Diagram, 3 Charts, 1 Graph.
Subjects: Malaria, Vaccines, Plasmodium falciparum, Children's health, Immunization of children, Diseases, Medical research, Preventive medicine
Geographic Terms: Mozambique
Abstract: Summary Background RTS,S/AS02A is a pre-erythrocytic stage malaria vaccine that provides partial protection against infection in malaria-naive adult volunteers and hyperimmune adults. A previous report showed that this vaccine reduced risk of clinical malaria, delayed time to new infection, and reduced episodes of severe malaria over 6 months in African children. An important remaining issue is the durability of protection against clinical disease in these children. Methods We did a randomised, controlled, phase IIb trial of RTS,S/AS02A given at 0, 1, and 2 months in 2022 Mozambican children aged 1-4 years. We previously determined vaccine efficacy (VE) against clinical malaria in a double-blind phase that included study months 2·5-8·5 (VE2·5-8·5). We now report VE in a single-blind phase up to month 21 (VE8·5-21). The primary endpoint was time to first or only clinical episode of Plasmodium falciparum malaria (axillary temperature ⩾37·5°C and P falciparum asexual parasitaemia >2500 per μL) detected through a passive case detection system. We also determined VE for other case definitions and for episodes of severe malaria. This study is registered with the ClinicalTrials.gov identifier NCT00197041. Findings During the single-blind phase, VE (8·5-21) was 28·9% (95% CI 8·4-44·8; p=0·008). At month 21, prevalence of P falciparum infection was 29% lower in the RTS,S/AS02A group than in the control (p=0·017). Considering the entire study period, VE (2·5-21) was 35·3% (95% CI 21·6-46·6; p<0·0001) and VE (2·5-21) for severe malaria was 48·6% (95% CI 12·3-71·0; p=0·02). Interpretation These results show that RTS,S/AS02A confers partial protection in African children aged 1-4 years living in rural endemic areas against a range of clinical disease caused by P falciparum for at least 18 months, and confirm the potential of malaria vaccines to become credible control tools for public-health use. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 19099388
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Alonso%2C+Pedro+L%2E%22&quot;&gt;Alonso, Pedro L.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sacarlal%2C+Jahit%22&quot;&gt;Sacarlal, Jahit&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aponte%2C+John+J%2E%22&quot;&gt;Aponte, John J.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Leach%2C+Amanda%22&quot;&gt;Leach, Amanda&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Macete%2C+Eusebio%22&quot;&gt;Macete, Eusebio&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aide%2C+Pedro%22&quot;&gt;Aide, Pedro&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sigauque%2C+Betuel%22&quot;&gt;Sigauque, Betuel&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Milman%2C+Jessica%22&quot;&gt;Milman, Jessica&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mandomando%2C+Inacio%22&quot;&gt;Mandomando, Inacio&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bassat%2C+Quique%22&quot;&gt;Bassat, Quique&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Guinovart%2C+Caterina%22&quot;&gt;Guinovart, Caterina&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Espasa%2C+Mateu%22&quot;&gt;Espasa, Mateu&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Corachan%2C+Sabine%22&quot;&gt;Corachan, Sabine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lievens%2C+Marc%22&quot;&gt;Lievens, Marc&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Navia%2C+Margarita+M%2E%22&quot;&gt;Navia, Margarita M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dubois%2C+Marie-Claude%22&quot;&gt;Dubois, Marie-Claude&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Menendez%2C+Clara%22&quot;&gt;Menendez, Clara&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dubovsky%2C+Filip%22&quot;&gt;Dubovsky, Filip&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cohen%2C+Joe%22&quot;&gt;Cohen, Joe&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Thompson%2C+Ricardo%22&quot;&gt;Thompson, Ricardo&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 12/10/2005, Vol. 366 Issue 9502, p2012-2018. 7p. 1 Diagram, 3 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Malaria%22&quot;&gt;Malaria&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Vaccines%22&quot;&gt;Vaccines&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Plasmodium+falciparum%22&quot;&gt;Plasmodium falciparum&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Children&#39;s+health%22&quot;&gt;Children&#39;s health&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Immunization+of+children%22&quot;&gt;Immunization of children&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Diseases%22&quot;&gt;Diseases&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+research%22&quot;&gt;Medical research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Preventive+medicine%22&quot;&gt;Preventive medicine&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Mozambique%22&quot;&gt;Mozambique&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Summary Background RTS,S/AS02A is a pre-erythrocytic stage malaria vaccine that provides partial protection against infection in malaria-naive adult volunteers and hyperimmune adults. A previous report showed that this vaccine reduced risk of clinical malaria, delayed time to new infection, and reduced episodes of severe malaria over 6 months in African children. An important remaining issue is the durability of protection against clinical disease in these children. Methods We did a randomised, controlled, phase IIb trial of RTS,S/AS02A given at 0, 1, and 2 months in 2022 Mozambican children aged 1-4 years. We previously determined vaccine efficacy (VE) against clinical malaria in a double-blind phase that included study months 2&#183;5-8&#183;5 (VE2&#183;5-8&#183;5). We now report VE in a single-blind phase up to month 21 (VE8&#183;5-21). The primary endpoint was time to first or only clinical episode of Plasmodium falciparum malaria (axillary temperature &amp;ges;37&#183;5&#176;C and P falciparum asexual parasitaemia &gt;2500 per μL) detected through a passive case detection system. We also determined VE for other case definitions and for episodes of severe malaria. This study is registered with the ClinicalTrials.gov identifier NCT00197041. Findings During the single-blind phase, VE (8&#183;5-21) was 28&#183;9% (95% CI 8&#183;4-44&#183;8; p=0&#183;008). At month 21, prevalence of P falciparum infection was 29% lower in the RTS,S/AS02A group than in the control (p=0&#183;017). Considering the entire study period, VE (2&#183;5-21) was 35&#183;3% (95% CI 21&#183;6-46&#183;6; p&lt;0&#183;0001) and VE (2&#183;5-21) for severe malaria was 48&#183;6% (95% CI 12&#183;3-71&#183;0; p=0&#183;02). Interpretation These results show that RTS,S/AS02A confers partial protection in African children aged 1-4 years living in rural endemic areas against a range of clinical disease caused by P falciparum for at least 18 months, and confirm the potential of malaria vaccines to become credible control tools for public-health use. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=19099388
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(05)67669-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 2012
    Subjects:
      – SubjectFull: Malaria
        Type: general
      – SubjectFull: Vaccines
        Type: general
      – SubjectFull: Plasmodium falciparum
        Type: general
      – SubjectFull: Children's health
        Type: general
      – SubjectFull: Immunization of children
        Type: general
      – SubjectFull: Diseases
        Type: general
      – SubjectFull: Medical research
        Type: general
      – SubjectFull: Preventive medicine
        Type: general
      – SubjectFull: Mozambique
        Type: general
    Titles:
      – TitleFull: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Alonso, Pedro L.
      – PersonEntity:
          Name:
            NameFull: Sacarlal, Jahit
      – PersonEntity:
          Name:
            NameFull: Aponte, John J.
      – PersonEntity:
          Name:
            NameFull: Leach, Amanda
      – PersonEntity:
          Name:
            NameFull: Macete, Eusebio
      – PersonEntity:
          Name:
            NameFull: Aide, Pedro
      – PersonEntity:
          Name:
            NameFull: Sigauque, Betuel
      – PersonEntity:
          Name:
            NameFull: Milman, Jessica
      – PersonEntity:
          Name:
            NameFull: Mandomando, Inacio
      – PersonEntity:
          Name:
            NameFull: Bassat, Quique
      – PersonEntity:
          Name:
            NameFull: Guinovart, Caterina
      – PersonEntity:
          Name:
            NameFull: Espasa, Mateu
      – PersonEntity:
          Name:
            NameFull: Corachan, Sabine
      – PersonEntity:
          Name:
            NameFull: Lievens, Marc
      – PersonEntity:
          Name:
            NameFull: Navia, Margarita M.
      – PersonEntity:
          Name:
            NameFull: Dubois, Marie-Claude
      – PersonEntity:
          Name:
            NameFull: Menendez, Clara
      – PersonEntity:
          Name:
            NameFull: Dubovsky, Filip
      – PersonEntity:
          Name:
            NameFull: Cohen, Joe
      – PersonEntity:
          Name:
            NameFull: Thompson, Ricardo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 12
              Text: 12/10/2005
              Type: published
              Y: 2005
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 366
            – Type: issue
              Value: 9502
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1